Tarceva

AZ's Tagrisso beats chemotherapy in lung cancer trial

The mutation develops in around two-thirds of patients who have received other EGFR inhibitors, such as Roche/Astellas' $2bn-a-year Tarceva (erlotinib), AstraZeneca's Iressa (gefitinib) and Boehringer

Reformed Cancer Drugs Fund backs its first drug - AZ’s Tagrisso

treatments, such as Roche and Astellas' Tarceva (erlotinib), AZ's Iressa (gefitinib) and Boehringer Ingelheim's Giotrif (afatinib).

Boehringer stops Gilotrif head and neck cancer trials

It is already vying in the marketplace against AstraZeneca's Iressa (gefitinib) and Roche/Astellas' Tarceva (erlotinib) in first-line NSCLC, and looks likely to face increased pressure with the availability

Astellas promotes John Demaree

Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib).

Roche gets EU okay for Avastin/Tarceva combination

Avastin targets VEGF while Tarceva is an EGFR inhibitor - pathways known to be drivers of tumour growth - and both are already approved individually as NSCLC therapies. ... Patients given the combination lived without disease progression for a median of

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]